Newsfeeds
Breaking World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.

World Pharma News
  • Clinical trial could change standard treatment for stroke
    A large international clinical trial has shed new light on the effectiveness of current hospital protocols for managing blood pressure in stroke patients. The two-part ENOS trial (Efficacy of Nitric Oxide in Stroke,) was carried out at The University of Nottingham in collaboration with 23 countries to try to solve two major conundrums faced by doctors when treating people who have suffered a stroke

  • Protecting us from our cells
    Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have found.

  • Analgesics and anti-inflammatory drugs may have an impact on depression
    Ordinary over the counter painkillers and anti-inflammatory drugs purchased from pharmacies may also be effective in the treatment of people suffering of depression. This is shown by the largest ever meta-analysis that has just been published by a research group from Aarhus University in the journal JAMA Psychiatry.

  • Viagra protects the heart beyond the bedroom
    Viagra could be used as a safe treatment for heart disease, finds new research published in the open access journal BMC Medicine. The study reveals that long-term daily treatment of Viagra can provide protection for the heart at different stages of heart disease, with few side effects.

  • Roche delivers solid sales growth for the first nine months of 2014
    RocheGroup sales were 34.8 billion Swiss francs, 5% higher at constant exchange rates and stable in Swiss francs for the nine months ended 30 September 2014. A number of currencies remained weaker against the Swiss franc throughout the year, most notably the US dollar, as well as all Latin American currencies and the Japanese yen.

  • Novo Nordisk second best science employer in the world
    Novo NordiskNovo Nordisk ranked second in the 2014 Science Careers Top Employers Survey, which is a big jump up the list from last year's ranking where Novo Nordisk came in at number 11. The key drivers of the ranking were the categories 'Treats employees with respect', 'Has loyal employees' and 'Is socially responsible'.

  • New cancer drug to begin trials in multiple myeloma patients
    Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. In a paper published in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs.

  • Tuning light to kill deep cancer tumors
    An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy.

  • Academies call for consequences from the Ebola virus epidemic
    The Ebola virus is spreading rapidly and to an unexpected extent. The outbreak does not follow the patterns experienced in the past and the virus shows a new disease dynamic in regions, where it has never been recorded before. For this reason, the German National Academy of Sciences Leopoldina, acatech - the German Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities have presented a statement on the Ebola epidemic.

  • Bio-inspired 'nano-cocoons' offer targeted drug delivery against cancer cells
    Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale "cocoons" made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.